{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:27:44Z","timestamp":1785907664121,"version":"3.56.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40264-022-01216-w","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:05:53Z","timestamp":1662480353000},"page":"1019-1036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-7838","authenticated-orcid":false,"given":"Johannes M. M.","family":"Boots","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier A. M.","family":"Quax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"1216_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1172\/JCI100478","volume":"11","author":"CW Heath","year":"1932","unstructured":"Heath CW, Strauss MB, Castle WB. Quantitative aspects of iron deficiency in hypochromic anemia. (The parenteral administration of iron). J Clin Invest. 1932;11:1293\u2013312. https:\/\/doi.org\/10.1172\/JCI100478.","journal-title":"J Clin Invest"},{"key":"1216_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood.V1.2.129.129","volume":"1","author":"AT Goetsch","year":"1946","unstructured":"Goetsch AT, Moore CV, Minnich V. Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia. Blood. 1946;1:129\u201342.","journal-title":"Blood"},{"issue":"6463","key":"1216_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0140-6736(47)90053-6","volume":"2","author":"JA Nissim","year":"1947","unstructured":"Nissim JA. Intravenous administration of iron. Lancet. 1947;2(6463):49\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(47)90053-6.","journal-title":"Lancet"},{"issue":"6556","key":"1216_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0140-6736(49)91958-3","volume":"1","author":"JA Nissim","year":"1949","unstructured":"Nissim JA, Robson JM. Preparation and standardisation of saccharated iron oxide for intravenous administration. Lancet. 1949;1(6556):686\u20139.","journal-title":"Lancet"},{"key":"1216_CR5","first-page":"880","volume":"24","author":"A M\u00fcller","year":"1974","unstructured":"M\u00fcller A. Classification and properties of iron preparations. Arzneimittelforschung (Drug Res). 1974;24:880\u20133.","journal-title":"Arzneimittelforschung (Drug Res)."},{"key":"1216_CR6","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.1016\/S0021-9258(19)86864-3","volume":"254","author":"EC Theil","year":"1979","unstructured":"Theil EC, Sayers DE, Brown MA. Similarity of the structure of ferritin and iron.dextran (Imferon) determined by extended X-ray absorption fine structure analysis. J Biol Chem. 1979;254:8132\u20134.","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"1216_CR7","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1111\/hdi.12560","volume":"21","author":"M Auerbach","year":"2017","unstructured":"Auerbach M, MacDougall I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial Int. 2017;21(Suppl 1):S83-92. https:\/\/doi.org\/10.1111\/hdi.12560.","journal-title":"Hemodial Int"},{"key":"1216_CR8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1001\/jama.1980.03300430028018","volume":"243","author":"RD Hamstra","year":"1980","unstructured":"Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. J Am Med Assoc. 1980;243:1726\u201331.","journal-title":"J Am Med Assoc"},{"key":"1216_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","volume":"90","author":"T Avni","year":"2015","unstructured":"Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12\u201323. https:\/\/doi.org\/10.1016\/j.mayocp.2014.10.007.","journal-title":"Mayo Clin Proc"},{"key":"1216_CR10","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/ndt\/gfh185","volume":"19","author":"GM Chertow","year":"2004","unstructured":"Chertow GM, Mason PD, Vaage-Nilsen O, Ahlm\u00e9n J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004;19:1571\u20135. https:\/\/doi.org\/10.1093\/ndt\/gfh185.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR11","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1093\/ndt\/gft062","volume":"28","author":"GR Bailie","year":"2013","unstructured":"Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013;28:2570\u20139. https:\/\/doi.org\/10.1093\/ndt\/gft062.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR12","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1046\/j.1523-1755.2002.00314.x","volume":"61","author":"B Michael","year":"2002","unstructured":"Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830\u20139. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00314.x.","journal-title":"Kidney Int"},{"key":"1216_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1046\/j.1523-1755.2003.00703.x","volume":"63","author":"DW Coyne","year":"2003","unstructured":"Coyne DW, Atkinson NF Jr, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003;63:217\u201324. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00703.x.","journal-title":"Kidney Int"},{"key":"1216_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/s0272-6386(99)70183-6","volume":"33","author":"G Faich","year":"1999","unstructured":"Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33:464\u201370. https:\/\/doi.org\/10.1016\/s0272-6386(99)70183-6.","journal-title":"Am J Kidney Dis"},{"key":"1216_CR15","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1053\/ajkd.2001.28587","volume":"38","author":"G Chandler","year":"2001","unstructured":"Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis. 2001;38:988\u201391. https:\/\/doi.org\/10.1053\/ajkd.2001.28587.","journal-title":"Am J Kidney Dis"},{"key":"1216_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ajh.25564","volume":"94","author":"M Auerbach","year":"2019","unstructured":"Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007\u201314. https:\/\/doi.org\/10.1002\/ajh.25564.","journal-title":"Am J Hematol"},{"key":"1216_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1447-0756.2012.01982.x","volume":"39","author":"PK Kochhar","year":"2013","unstructured":"Kochhar PK, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in the treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. J Obstet Gynaecol Res. 2013;39:504\u201310. https:\/\/doi.org\/10.1111\/j.1447-0756.2012.01982.x.","journal-title":"J Obstet Gynaecol Res"},{"key":"1216_CR18","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/j.1572-0241.2005.00250.x","volume":"100","author":"O Schr\u00f6der","year":"2005","unstructured":"Schr\u00f6der O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease\u2014a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503\u20139. https:\/\/doi.org\/10.1111\/j.1572-0241.2005.00250.x.","journal-title":"Am J Gastroenterol"},{"key":"1216_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/00365520902839667","volume":"44","author":"S Lindgren","year":"2009","unstructured":"Lindgren S, Wikman O, Berits R, Blom H, Eriksson A, Gr\u00e4nn\u00f6 C, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator blind, multicentre study. Scand J Gastroenterol. 2009;44:838\u201345. https:\/\/doi.org\/10.1080\/00365520902839667.","journal-title":"Scand J Gastroenterol"},{"key":"1216_CR20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/ndt\/gfs528","volume":"28","author":"C Charytan","year":"2013","unstructured":"Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant. 2013;28:953\u201364. https:\/\/doi.org\/10.1093\/ndt\/gfs528.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijgo.2007.10.009","volume":"101","author":"C Breymann","year":"2008","unstructured":"Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101:67\u201373. https:\/\/doi.org\/10.1016\/j.ijgo.2007.10.009.","journal-title":"Int J Gynaecol Obstet"},{"issue":"435","key":"1216_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2008.07.046","volume":"199","author":"MH Seid","year":"2008","unstructured":"Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(435):e1-7. https:\/\/doi.org\/10.1016\/j.ajog.2008.07.046.","journal-title":"Am J Obstet Gynecol"},{"key":"1216_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2326-11-4","author":"RA Moore","year":"2011","unstructured":"Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders. 2011. https:\/\/doi.org\/10.1186\/1471-2326-11-4.","journal-title":"BMC Blood Disorders."},{"key":"1216_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/172104","author":"CF Barish","year":"2012","unstructured":"Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia. 2012. https:\/\/doi.org\/10.1155\/2012\/172104.","journal-title":"Anemia."},{"key":"1216_CR25","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","volume":"49","author":"DB Van Wyck","year":"2009","unstructured":"Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719\u201328. https:\/\/doi.org\/10.1111\/j.1537-2995.2009.02327.x.","journal-title":"Transfusion"},{"key":"1216_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.AOG.0000275286.03283.18","volume":"110","author":"DB Van Wyck","year":"2007","unstructured":"Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110:267\u201378. https:\/\/doi.org\/10.1097\/01.AOG.0000275286.03283.18.","journal-title":"Obstet Gynecol"},{"key":"1216_CR27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","volume":"26","author":"WY Qunibi","year":"2011","unstructured":"Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599\u2013607. https:\/\/doi.org\/10.1093\/ndt\/gfq613.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/815437","author":"N Becuzzi","year":"2014","unstructured":"Becuzzi N, Zimmermann R, Krafft A. Long-term efficacy of postpartum intravenous iron therapy. Biomed Res Int. 2014. https:\/\/doi.org\/10.1155\/2014\/815437.","journal-title":"Biomed Res Int"},{"key":"1216_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-019-2200-3","author":"A Jose","year":"2019","unstructured":"Jose A, Mahey R, Sharma JB, Bhatla N, Saxena R, Kalaivani M, et al. Comparison of ferric carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy-randomised controlled trial. BMC Pregnancy Childbirth. 2019. https:\/\/doi.org\/10.1186\/s12884-019-2200-3.","journal-title":"BMC Pregnancy Childbirth"},{"key":"1216_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/trf.12289","volume":"54","author":"JE Onken","year":"2014","unstructured":"Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, et al. A multicenter, randomized, active-controlled study to investigate the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54:306\u201315. https:\/\/doi.org\/10.1111\/trf.12289.","journal-title":"Transfusion"},{"key":"1216_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2362.2009.02130.x","volume":"39","author":"VS Balakrishnan","year":"2009","unstructured":"Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJG, Frigo TB, et al. Physiochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009;39:489\u201396. https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02130.x.","journal-title":"Eur J Clin Invest"},{"key":"1216_CR32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","volume":"78","author":"MR Jahn","year":"2011","unstructured":"Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78:480\u201391. https:\/\/doi.org\/10.1016\/j.ejpb.2011.03.016.","journal-title":"Eur J Pharm Biopharm"},{"key":"1216_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5301\/JN.2011.6248","volume":"24","author":"B Wikstrom","year":"2011","unstructured":"Wikstrom B, Bhandari S, Barany P, Kalra PA, Ladefoged S, Wilske J, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24:589\u201396. https:\/\/doi.org\/10.5301\/JN.2011.6248.","journal-title":"J Nephrol"},{"key":"1216_CR34","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/ajg.2013.335","volume":"108","author":"W Reinisch","year":"2013","unstructured":"Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877\u201388. https:\/\/doi.org\/10.1038\/ajg.2013.335.","journal-title":"Am J Gastroenterol"},{"key":"1216_CR35","first-page":"13","volume":"26","author":"PA Kalra","year":"2012","unstructured":"Kalra PA, Bock K, Meldal M. Iron isomaltoside 1000: a new high dose option for parenteral iron therapy. Port J Nephrol Hypert. 2012;26:13\u201324.","journal-title":"Port J Nephrol Hypert."},{"key":"1216_CR36","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436\u201348. https:\/\/doi.org\/10.1056\/NEJMoa0908355.","journal-title":"N Engl J Med"},{"key":"1216_CR37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symtomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385.","journal-title":"Eur Heart J"},{"key":"1216_CR38","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","volume":"136","author":"DJ van Veldhuisen","year":"2017","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, B\u00f6hm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136:1374\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.027497.","journal-title":"Circulation"},{"key":"1216_CR39","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan B, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4.","journal-title":"Lancet"},{"key":"1216_CR40","first-page":"49","volume":"72","author":"A Blazevic","year":"2014","unstructured":"Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med. 2014;72:49\u201353.","journal-title":"Neth J Med"},{"key":"1216_CR41","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/TP.0b013e3181f00a18","volume":"90","author":"LY Mani","year":"2010","unstructured":"Mani LY, Nseir G, Venetz JP, Pascual M. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation. 2010;90:804\u20135. https:\/\/doi.org\/10.1097\/TP.0b013e3181f00a18.","journal-title":"Transplantation"},{"key":"1216_CR42","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94:2332\u20137. https:\/\/doi.org\/10.1210\/jc.2008-2396.","journal-title":"J Clin Endocrinol Metab"},{"key":"1216_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.medcli.2014.10.016","volume":"145","author":"R S\u00e1chez Gonz\u00e1lez","year":"2015","unstructured":"S\u00e1chez Gonz\u00e1lez R, Ternavasio-de la Vega HG, Moralejo Alonso L, Ines Revuelta S, Fuertes MA. Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia A common side effect. Med Clin (Barc). 2015;145:108\u201311. https:\/\/doi.org\/10.1016\/j.medcli.2014.10.016.","journal-title":"Med Clin (Barc)"},{"key":"1216_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.medcli.2013.11.030","volume":"143","author":"JA Barea Mendoza","year":"2014","unstructured":"Barea Mendoza JA, Gredilla Zubiria I, Gonzalez Olmedo J, Mateo AS. Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron. Med Clin (Barc). 2014;143:284\u20135. https:\/\/doi.org\/10.1016\/j.medcli.2013.11.030.","journal-title":"Med Clin (Barc)"},{"key":"1216_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ejcn.2014.20","volume":"68","author":"YC Fierz","year":"2014","unstructured":"Fierz YC, Kenmeni R, Gonthier A, Lier F, Pralong F, Coti BP. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr. 2014;68:531\u20133. https:\/\/doi.org\/10.1038\/ejcn.2014.20.","journal-title":"Eur J Clin Nutr"},{"key":"1216_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/843689","author":"X Vandemergel","year":"2014","unstructured":"Vandemergel X, Vandergheynst F. Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: A case report and review of the literature. Case Rep Endocrinol. 2014. https:\/\/doi.org\/10.1155\/2014\/843689.","journal-title":"Case Rep Endocrinol."},{"key":"1216_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-219160","author":"G Anand","year":"2017","unstructured":"Anand G, Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep. 2017. https:\/\/doi.org\/10.1136\/bcr-2016-219160.","journal-title":"BMJ Case Rep"},{"key":"1216_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/ygh2.415","author":"KC Fragkos","year":"2020","unstructured":"Fragkos KC, Sehgal V, Rogers J, Arulrajan S, Pavanerathan P, Barragry J, et al. Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose\u2014real world experience from a tertiary centre in the UK. GastroHep. 2020. https:\/\/doi.org\/10.1002\/ygh2.415.","journal-title":"GastroHep."},{"key":"1216_CR49","doi-asserted-by":"publisher","DOI":"10.12890\/2020_001860","author":"KK Teh","year":"2020","unstructured":"Teh KK, Chuah MB, Tay S, Lim AY, Khoo JJ. Severe hypophosphataemia as a complication of parenteral iron replacement. Eur J Case Rep Int Med. 2020. https:\/\/doi.org\/10.12890\/2020_001860.","journal-title":"Eur J Case Rep Int Med."},{"key":"1216_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TCRM.S243462","volume":"16","author":"JA Glaspy","year":"2020","unstructured":"Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag. 2020;16:245\u201359. https:\/\/doi.org\/10.2147\/TCRM.S243462.","journal-title":"Ther Clin Risk Manag"},{"key":"1216_CR51","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","volume":"26","author":"H Zoller","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B. Iron-induced hypophophatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26:266\u201375. https:\/\/doi.org\/10.1097\/MNH.0000000000000329.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"1216_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094217","volume":"9","author":"B Favrat","year":"2014","unstructured":"Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women\u2014PREFER a randomized, placebo-controlled study. PLoS ONE. 2014;9(4): e94217. https:\/\/doi.org\/10.1371\/journal.pone.0094217.","journal-title":"PLoS ONE"},{"key":"1216_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","volume":"23","author":"M Wolf","year":"2014","unstructured":"Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014;23:411\u20139. https:\/\/doi.org\/10.1097\/01.mnh.0000447020.74593.6f.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1216_CR54","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793\u2013803. https:\/\/doi.org\/10.1002\/jbmr.1923.","journal-title":"J Bone Miner Res"},{"key":"1216_CR55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153329","author":"X Li","year":"2021","unstructured":"Li X, Lozovatsky L, Fretz JA, Finberg KE. Bone marrow sinusoidal endothelial cells are a site of Fgf23 upregulation in iron deficiency anemia. Blood. 2021. https:\/\/doi.org\/10.1182\/blood-2021-153329.","journal-title":"Blood"},{"key":"1216_CR56","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"232","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects on iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia. J Am Med Assoc. 2020;232:432\u201343. https:\/\/doi.org\/10.1001\/jama.2019.22450.","journal-title":"J Am Med Assoc"},{"key":"1216_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115559","author":"R Frazier","year":"2020","unstructured":"Frazier R, Hodakowski A, Cai X, Lee J, Zakarija A, Stein B, et al. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: a single-center prospective study of women with iron deficiency. Bone. 2020. https:\/\/doi.org\/10.1016\/j.bone.2020.115559.","journal-title":"Bone"},{"key":"1216_CR58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124486","author":"M Wolf","year":"2018","unstructured":"Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.124486.","journal-title":"JCI Insight."},{"key":"1216_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00424-018-2238-5","volume":"471","author":"MC Hu","year":"2019","unstructured":"Hu MC, Shi M, Moe OW. Role of alpha-Klotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters. Pflugers Arch. 2019;471:99\u2013108. https:\/\/doi.org\/10.1007\/s00424-018-2238-5.","journal-title":"Pflugers Arch"},{"key":"1216_CR60","doi-asserted-by":"publisher","first-page":"F1088","DOI":"10.1152\/ajprenal.00474.2004","volume":"289","author":"T Shimada","year":"2005","unstructured":"Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088\u201395. https:\/\/doi.org\/10.1152\/ajprenal.00474.2004.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1216_CR61","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Nat Acad Sci U S A. 2001;98:6500\u20135. https:\/\/doi.org\/10.1073\/pnas.101545198.","journal-title":"Proc Nat Acad Sci U S A."},{"key":"1216_CR62","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1210\/en.2004-0354","volume":"145","author":"T Larsson","year":"2004","unstructured":"Larsson T, Mardell R, Schipani E, Ohlsson C, Ljunggren O, Tenehouse HS, et al. Transgenic mice expressing fibroblast growth factor 23 under the controle of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3084\u20136. https:\/\/doi.org\/10.1210\/en.2004-0354.","journal-title":"Endocrinology"},{"key":"1216_CR63","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429\u201335. https:\/\/doi.org\/10.1359\/JBMR.0301264.","journal-title":"J Bone Miner Res"},{"key":"1216_CR64","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/j.jacc.2018.03.448","volume":"71","author":"R St\u00f6hr","year":"2018","unstructured":"St\u00f6hr R, Sandstede L, Heine GH, Marx N, Brandenburg V. High-dose ferric carboxymaltose in patients with HFrEF induces significant hypophosphatemia. J Am Coll Cardiol. 2018;71:2270\u20131. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.448.","journal-title":"J Am Coll Cardiol"},{"key":"1216_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01643-5","author":"IE Emrich","year":"2020","unstructured":"Emrich IE, Lizzi F, Siegel JD, Seiler-Mussler S, Ukena C, Kaddu-Mulindwa D, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose - the randomized controlled HOMe aFers study. BMC Med. 2020. https:\/\/doi.org\/10.1186\/s12916-020-01643-5.","journal-title":"BMC Med"},{"key":"1216_CR66","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/rheumatology\/kez675","volume":"59","author":"R Amarnani","year":"2020","unstructured":"Amarnani R, Travis S, Javaid MK. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Rheumatology. 2020;59:2168\u201370. https:\/\/doi.org\/10.1093\/rheumatology\/kez675.","journal-title":"Rheumatology"},{"key":"1216_CR67","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S89704","volume":"9","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer((R))) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016;9:53\u201364. https:\/\/doi.org\/10.2147\/IJNRD.S89704.","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"1216_CR68","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1080\/00365521.2016.1196496","volume":"51","author":"JF Dahlerup","year":"2016","unstructured":"Dahlerup JF, Jacobsen BA, van der Woude J, Bark L, Thomsen LL, Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51:1332\u20138. https:\/\/doi.org\/10.1080\/00365521.2016.1196496.","journal-title":"Scand J Gastroenterol"},{"key":"1216_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167146","author":"B Schaefer","year":"2016","unstructured":"Schaefer B, W\u00fcrtinger P, Finkenstedt A, Braithwaite V, Viveiros A, Effenberger M, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0167146.","journal-title":"PLoS ONE"},{"key":"1216_CR70","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/apt.15386","volume":"50","author":"TE Detlie","year":"2019","unstructured":"Detlie TE, Lindstr\u00f8m JC, Jahnsen ME, Finnes E, Zoller H, Moum B, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50:397\u2013406. https:\/\/doi.org\/10.1111\/apt.15386.","journal-title":"Aliment Pharmacol Ther"},{"key":"1216_CR71","doi-asserted-by":"crossref","unstructured":"Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, et al. Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to inflammatory bowel disease: a phase IV randomised clinical trial. https:\/\/www.ecco-ibd.eu: Abstract DOP89 ECCO 2021. Accessed 18 Aug 2022.","DOI":"10.1093\/ecco-jcc\/jjab073.128"},{"key":"1216_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14643","author":"B Schaefer","year":"2020","unstructured":"Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta-analysis. Br J Clin Pharmacol. 2020. https:\/\/doi.org\/10.1111\/bcp.14643.","journal-title":"Br J Clin Pharmacol"},{"key":"1216_CR73","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ajh.24633","volume":"92","author":"R Derman","year":"2017","unstructured":"Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92:286\u201391. https:\/\/doi.org\/10.1002\/ajh.24633.","journal-title":"Am J Hematol"},{"key":"1216_CR74","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/169107","author":"I Hussain","year":"2013","unstructured":"Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia. 2013. https:\/\/doi.org\/10.1155\/2013\/169107.","journal-title":"Anemia."},{"key":"1216_CR75","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","volume":"107","author":"B Schaefer","year":"2022","unstructured":"Schaefer B, Zoller HWM. Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose. J Clin Endocrinol Metab. 2022;107:1009\u201319. https:\/\/doi.org\/10.1210\/clinem\/dgab852.","journal-title":"J Clin Endocrinol Metab"},{"key":"1216_CR76","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/468675","author":"S Hardy","year":"2015","unstructured":"Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015. https:\/\/doi.org\/10.1155\/2015\/468675.","journal-title":"Int J Rheumatol"},{"key":"1216_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113587","author":"G Rosano","year":"2020","unstructured":"Rosano G, Schiefke I, G\u00f6hring U, Fabien V, Bonassi S, Stein J. A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9113587.","journal-title":"J Clin Med"},{"key":"1216_CR78","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00394-018-1672-7","volume":"58","author":"C Trummer","year":"2019","unstructured":"Trummer C, Schwetz V, Pandis M, Gr\u00fcbler MR, Verheyen N, Gaksch M, et al. Effects of vitamin D supplementation on FGF-23: A randomized-controlled trial. Eur J Nutr. 2019;58:697\u2013703. https:\/\/doi.org\/10.1007\/s00394-018-1672-7.","journal-title":"Eur J Nutr"},{"key":"1216_CR79","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s11695-020-04544-x","volume":"30","author":"M Schoeb","year":"2020","unstructured":"Schoeb M, R\u00e4ss A, Frei N, Acz\u00e9l S, Br\u00e4ndle M, Bilz S. High risk of hypophosphatemia in patients with previous bariatric surgery receiving ferric carboxymaltose: a prospective cohort study. Obes Surg. 2020;30:2659\u201366. https:\/\/doi.org\/10.1007\/s11695-020-04544-x.","journal-title":"Obes Surg"},{"key":"1216_CR80","first-page":"65","volume":"75","author":"V Sari","year":"2017","unstructured":"Sari V, Atiqi R, Hoorn EJ, Heijboer AC, van Gelder T, Hesselink DA. Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation. Neth J Med. 2017;75:65\u201373.","journal-title":"Neth J Med"},{"key":"1216_CR81","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/imj.13001","volume":"46","author":"B Smyth","year":"2016","unstructured":"Smyth B, Ong S. Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction. Intern Med J. 2016;46:360\u20133. https:\/\/doi.org\/10.1111\/imj.13001.","journal-title":"Intern Med J"},{"key":"1216_CR82","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1159\/000518363","volume":"52","author":"G Cianciolo","year":"2021","unstructured":"Cianciolo G, Tondolo F, Barbuto S, Iacovella F, Zavatta G, Altieri P, et al. Denosumab-induced hypocalcemia and hyperparathyroidism in de novo kidney transplant recipients. Am J Nephrol. 2021;52:611\u20139. https:\/\/doi.org\/10.1159\/000518363.","journal-title":"Am J Nephrol"},{"key":"1216_CR83","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365. https:\/\/doi.org\/10.1056\/NEJMoa0809493.","journal-title":"N Engl J Med"},{"key":"1216_CR84","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","volume":"31","author":"G Tsvetov","year":"2020","unstructured":"Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T. Denosumab-induced hypocalcemia in patients with osteoprosis: can you know who will get low? Osteoporos Int. 2020;31:655\u201365. https:\/\/doi.org\/10.1007\/s00198-019-05261-7.","journal-title":"Osteoporos Int"},{"key":"1216_CR85","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00774-020-01180-4","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Mizutani H, Tsuruya E, Fukuda R, Kuge K, Okubo N. Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. J Bone Miner Metab. 2021;39:463\u201373. https:\/\/doi.org\/10.1007\/s00774-020-01180-4.","journal-title":"J Bone Miner Metab"},{"key":"1216_CR86","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00223-020-00754-8","volume":"107","author":"KJ Kim","year":"2020","unstructured":"Kim KJ, Hong N, Lee S, Kim M, Rhee Y. A simple-to-use score for identifying individuals at high risk of denosumab-associated hypocalcemia in postmenopausal osteoprosis: a real-world cohort study. Calcif Tissue Int. 2020;107:567\u201375. https:\/\/doi.org\/10.1007\/s00223-020-00754-8.","journal-title":"Calcif Tissue Int"},{"key":"1216_CR87","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","volume":"25","author":"ALH Huynh","year":"2016","unstructured":"Huynh ALH, Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016;25:1274\u20138. https:\/\/doi.org\/10.1002\/pds.4045.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1216_CR88","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/TCRM.S123172","volume":"12","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa K, Nagai T, Sakamoto K, Ohara K, Euro T, Ito H, et al. High bone turnover elevates risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag. 2016;12:1831\u201340. https:\/\/doi.org\/10.2147\/TCRM.S123172.","journal-title":"Ther Clin Risk Manag"},{"key":"1216_CR89","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/flgastro-2019-101242","volume":"11","author":"RE Harris","year":"2019","unstructured":"Harris RE, Armstrong L, Curtis L, Garrick VG, Tayler R, Hansen R, et al. Severe hypophosphataemia following ferric carboxymaltose infusion in paediatric patients with inflammatory bowel disease. Frontline Gastroenterol. 2019;11:324\u20136. https:\/\/doi.org\/10.1136\/flgastro-2019-101242.","journal-title":"Frontline Gastroenterol."},{"key":"1216_CR90","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.dld.2021.02.017","volume":"53","author":"L Cococcioni","year":"2021","unstructured":"Cococcioni L, Pensabene L, El-Khouly S, Chadokufa S, McCartney S, Saliakellis E, et al. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia. Dig Liver Dis. 2021;53:830\u20134. https:\/\/doi.org\/10.1016\/j.dld.2021.02.017.","journal-title":"Dig Liver Dis"},{"key":"1216_CR91","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/apa.15178","volume":"109","author":"A Posod","year":"2020","unstructured":"Posod A, Schaefer B, Mueller T, Zoller H, Kiechl-Kohlendorfer U. Hypophosphatemia in children treated with ferric carboxymaltose. Acta Paediatr. 2020;109:1491\u20132. https:\/\/doi.org\/10.1111\/apa.15178.","journal-title":"Acta Paediatr"},{"key":"1216_CR92","doi-asserted-by":"publisher","first-page":"E215","DOI":"10.1002\/ajh.26165","volume":"96","author":"SE Kirk","year":"2021","unstructured":"Kirk SE, Scheurer ME, Bernhardt MB, Mahoney DH, Powers JM. Phosphorus levels in children treated with intravenous ferric carboxymaltose. Am J Hematol. 2021;96:E215\u20138. https:\/\/doi.org\/10.1002\/ajh.26165.","journal-title":"Am J Hematol"},{"key":"1216_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-018-0919-8","author":"SF Boettger","year":"2018","unstructured":"Boettger SF, Angersbach B, Klimek CN, Monteiro Wanderley AL, Shaibekov A, Sieske L, et al. Prevalence and predictors of vitamin D-deficiency in frail and older hospitalized patients. BMC Geriatr. 2018. https:\/\/doi.org\/10.1186\/s12877-018-0919-8.","journal-title":"BMC Geriatr"},{"key":"1216_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-0695-x","author":"C Duarte","year":"2020","unstructured":"Duarte C, Carvalheiro H, Rodrigues AM, Dias SS, Marques A, Santiago T, et al. Prevalence of vitamin D deficiency and its predictors in the Portuguese population: a nationwide population-based study. Arch Osteoporos. 2020. https:\/\/doi.org\/10.1007\/s11657-020-0695-x.","journal-title":"Arch Osteoporos"},{"key":"1216_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56297-y","author":"J Wei","year":"2019","unstructured":"Wei J, Zhu A, Ji JS. A comparison study of vitamin D deficiency among older adults in China and the United States. Sci Rep. 2019. https:\/\/doi.org\/10.1038\/s41598-019-56297-y.","journal-title":"Sci Rep"},{"key":"1216_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/nu12030737","author":"M Besora-Moreno","year":"2020","unstructured":"Besora-Moreno M, Llaurad\u00f3 E, Tarro L, Sol\u00e0 R. Social and Economic factors and malnutrition or the risk of malnutrition in the elderly: a systematic review and meta-analysis of observational studies. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12030737.","journal-title":"Nutrients"},{"key":"1216_CR97","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1017\/S0029665118002628","volume":"78","author":"CA Corish","year":"2019","unstructured":"Corish CA, Bardon LA. Malnutrition in older adults: screening and determinants. Proc Nutr Soc. 2019;78:372\u20139. https:\/\/doi.org\/10.1017\/S0029665118002628.","journal-title":"Proc Nutr Soc"},{"key":"1216_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020499","author":"BN Ames","year":"2021","unstructured":"Ames BN, Grant WB, Willett WC. Does the high prevalence of vitamin D deficiency in African Americans contribute to health disparities? Nutrients. 2021. https:\/\/doi.org\/10.3390\/nu13020499.","journal-title":"Nutrients"},{"key":"1216_CR99","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jbmr.3878","volume":"35","author":"EA Imel","year":"2020","unstructured":"Imel EA, Liu Z, Coffman M, Acton D, Mehta R, Econs MJ. Oral iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophophatemic rickets. J Bone Miner Res. 2020;35:231\u20138. https:\/\/doi.org\/10.1002\/jbmr.3878.","journal-title":"J Bone Miner Res"},{"key":"1216_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115137","author":"LP Menon","year":"2020","unstructured":"Menon LP, Weinstein RS. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: a review of the role of iron. Bone. 2020. https:\/\/doi.org\/10.1016\/j.bone.2019.115137.","journal-title":"Bone"},{"key":"1216_CR101","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000327019","volume":"33","author":"Y Takeda","year":"2011","unstructured":"Takeda Y, Komaba H, Goto S, Fuji H, Umezu M, Hasegawa H, et al. Effect of intravenous saccharated ferric oxide in serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol. 2011;33:421\u20136. https:\/\/doi.org\/10.1159\/000327019.","journal-title":"Am J Nephrol"},{"key":"1216_CR102","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/jci46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu M, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393\u2013408. https:\/\/doi.org\/10.1172\/jci46122.","journal-title":"J Clin Invest"},{"key":"1216_CR103","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/jamacardio.2018.0653","volume":"3","author":"BA Bergmark","year":"2018","unstructured":"Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, et al. Association of fibroblast growth factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2018;3:473\u201380. https:\/\/doi.org\/10.1001\/jamacardio.2018.0653.","journal-title":"JAMA Cardiol."},{"key":"1216_CR104","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","volume":"152","author":"BD Parker","year":"2010","unstructured":"Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152:640\u20138. https:\/\/doi.org\/10.7326\/0003-4819-152-10-201005180-00004.","journal-title":"Ann Intern Med"},{"key":"1216_CR105","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25:349\u201360. https:\/\/doi.org\/10.1681\/ASN.2013050465.","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR106","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","volume":"31","author":"M Leifheit-Nestler","year":"2016","unstructured":"Leifheit-Nestler M, Gro\u00dfe Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, et al. Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:1088\u201399. https:\/\/doi.org\/10.1093\/ndt\/gfv421.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR107","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/ndt\/gft456","volume":"29","author":"A Bouma-de Krijger","year":"2014","unstructured":"Bouma-de Krijger A, Bots ML, Vervloet M, Blankestijn PJ, ter Wee PW, van Zuilen AD, et al. Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant. 2014;29:88\u201397. https:\/\/doi.org\/10.1093\/ndt\/gft456.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR108","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2215\/CJN.07870713","volume":"9","author":"S Seiler","year":"2014","unstructured":"Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2\u20134. Clin J Am Soc Nephrol. 2014;9:1049\u201358. https:\/\/doi.org\/10.2215\/CJN.07870713.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1216_CR109","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risk of mortality and end-stage renal disease in patients with chronic kidney disease. J Am Med Assoc. 2011;305:2432\u20139. https:\/\/doi.org\/10.1001\/jama.2011.826.","journal-title":"J Am Med Assoc"},{"key":"1216_CR110","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1681\/ASN.2012070713","volume":"24","author":"JJ Scialla","year":"2013","unstructured":"Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M. Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol. 2013;24:125\u201335. https:\/\/doi.org\/10.1681\/ASN.2012070713.","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR111","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.ekir.2019.07.022","volume":"4","author":"S Sharma","year":"2019","unstructured":"Sharma S, Hanudel MR, Ix JH, Salusky IB, Ganz T, Nguyen K. Elevated fibroblast growth factor 23 levels are associated with greater diastolic dysfunction in ESRD. Kidney Int Rep. 2019;4:1748\u201351. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.022.","journal-title":"Kidney Int Rep."},{"key":"1216_CR112","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.ekir.2020.08.013","volume":"5","author":"H Komaba","year":"2020","unstructured":"Komaba H, Fuller DS, Taniguchi M, Yamamoto S, Nomura T, Zhao J, et al. Fibroblast growth factor 23 and mortality among prevalent hemodialysis patients in the Japan dialysis outcomes and practice study. Kidney Int Rep. 2020;5:1956\u201364. https:\/\/doi.org\/10.1016\/j.ekir.2020.08.013.","journal-title":"Kidney Int Rep."},{"key":"1216_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100688","author":"A Nowak","year":"2014","unstructured":"Nowak A, Friedrich B, Artunc F, Serra AL, Breidthardt T, Twerenbold R, et al. Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients. PLoS ONE. 2014. https:\/\/doi.org\/10.1371\/journal.pone.0100688.","journal-title":"PLoS ONE"},{"key":"1216_CR114","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1681\/ASN.2014101009","volume":"27","author":"M Chonchoi","year":"2016","unstructured":"Chonchoi M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol. 2016;27:227\u201337. https:\/\/doi.org\/10.1681\/ASN.2014101009.","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR115","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584\u201392. https:\/\/doi.org\/10.1056\/NEJMoa0706130.","journal-title":"N Engl J Med"},{"key":"1216_CR116","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000497445","volume":"49","author":"A Jovanovich","year":"2019","unstructured":"Jovanovich A, You Z, Isakova T, Now K, Cheung A, Wolf M, et al. Fibroblast growth factor 23 trajectories in chronic hemodialysis patients: Lessons from the HEMO study. Am J Nephrol. 2019;49:263\u201370. https:\/\/doi.org\/10.1159\/000497445.","journal-title":"Am J Nephrol"},{"key":"1216_CR117","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.011130","author":"MF Eisenga","year":"2019","unstructured":"Eisenga MF, Emans ME, van der Putten K, Cramer MJ, Diepenbroek A, Velthuis BK, et al. Epoietin beta and c-terminal fibroblast growth factor 23 in patients with chronic heart failure and chronic kidney disease. J Am Heart Assoc. 2019. https:\/\/doi.org\/10.1161\/jaha.118.011130.","journal-title":"J Am Heart Assoc"},{"key":"1216_CR118","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1053\/j.gastro.2016.09.050","volume":"152","author":"B Schaefer","year":"2017","unstructured":"Schaefer B, Glodny B, Zoller H. Blood and bone loser. Gastroenterology. 2017;152:e5-6. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.050.","journal-title":"Gastroenterology"},{"key":"1216_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100712","author":"EL Callejas-Moraga","year":"2020","unstructured":"Callejas-Moraga EL, Casado E, Gomez-Nu\u00f1ez M, Caresia-Aroztegui AP. Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome. Bone Rep. 2020. https:\/\/doi.org\/10.1016\/j.bonr.2020.100712.","journal-title":"Bone Rep."},{"key":"1216_CR120","doi-asserted-by":"publisher","first-page":"4","DOI":"10.13107\/jocr.2019.v10.i01.1612","volume":"10","author":"D Tozzi","year":"2020","unstructured":"Tozzi D, Tozzi J. Osteomalacia and insufficiency fractures secondary to intravenous iron therpay: A case report. J Orthop Case Rep. 2020;10:4\u20137. https:\/\/doi.org\/10.13107\/jocr.2019.v10.i01.1612.","journal-title":"J Orthop Case Rep."},{"key":"1216_CR121","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-222851","author":"K Klein","year":"2018","unstructured":"Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018. https:\/\/doi.org\/10.1136\/bcr-2017-222851.","journal-title":"BMJ Case Rep"},{"key":"1216_CR122","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jbmr.3319","volume":"33","author":"J Bartko","year":"2018","unstructured":"Bartko J, R\u00f6scher P, Zandieh S, Brehm A, Zwerina J, Klaushofer K. Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report. J Bone Miner Res. 2018;33:534\u20139. https:\/\/doi.org\/10.1002\/jbmr.3319.","journal-title":"J Bone Miner Res"},{"key":"1216_CR123","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.remn.2016.04.006","volume":"35","author":"MJ Sangr\u00f3s Sah\u00fan","year":"2016","unstructured":"Sangr\u00f3s Sah\u00fan MJ, Go\u00f1i Giron\u00e9s E, Camarero Salazar A, Est\u00e9banez EC. Symptomatic hypophosphataemic osteomalacia secondary to treatment with ferric carboxymaltose detected in bone scintigraphy. Rev Esp Med Nucl Imagen Mol. 2016;35:391\u20133. https:\/\/doi.org\/10.1016\/j.remn.2016.04.006.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"1216_CR124","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/jgh3.12150","volume":"3","author":"W Fang","year":"2019","unstructured":"Fang W, McMahon LP, Bloom S, Gargantuas M. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose. JGH Open. 2019;3:438\u201340. https:\/\/doi.org\/10.1002\/jgh3.12150.","journal-title":"JGH Open."},{"key":"1216_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4558","author":"T Vilaca","year":"2022","unstructured":"Vilaca T, Velmurugan N, Smith C, Abrahamsen B, Eastell R. Osteomalacia as a complication of intravenous iron infusion: a systematic review of case-reports. J Bone Miner Res. 2022. https:\/\/doi.org\/10.1002\/jbmr.4558.","journal-title":"J Bone Miner Res"},{"key":"1216_CR126","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1258\/acb.2008.008151","volume":"46","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009;46:167\u20139. https:\/\/doi.org\/10.1258\/acb.2008.008151.","journal-title":"Ann Clin Biochem"},{"key":"1216_CR127","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/2042018816678363","volume":"8","author":"RH Bishay","year":"2017","unstructured":"Bishay RH, Ganda K, Seibel MJ. Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: A report of two cases and review of the literature. Thor Adv Endocrinol Metab. 2017;8:14\u20139. https:\/\/doi.org\/10.1177\/2042018816678363.","journal-title":"Thor Adv Endocrinol Metab."},{"key":"1216_CR128","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1675654","author":"D Ishimaru","year":"2017","unstructured":"Ishimaru D, Sumi H. A case of insufficiency fracture of the medial proximal tibia secondary to osteomalacia associated with long-term saccharated ferric oxide administration. Case Rep Orthop. 2017. https:\/\/doi.org\/10.1155\/2017\/1675654.","journal-title":"Case Rep Orthop"},{"key":"1216_CR129","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7888\/juoeh.35.25","volume":"35","author":"S Yamamoto","year":"2013","unstructured":"Yamamoto S, Okada Y, Mori H, Kurozumi A, Torimoto K, Arao T, et al. Iatrogenic osteomalacia: report of two cases. J UOEH. 2013;35:25\u201331. https:\/\/doi.org\/10.7888\/juoeh.35.25.","journal-title":"J UOEH"},{"key":"1216_CR130","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s8756-3282(97)00084-7","volume":"21","author":"K Sato","year":"1997","unstructured":"Sato K, Nohtomi K, Demura H, Takeuchi A, Kobayashi T, Kazama J, et al. Saccharated ferric oxide (SFO)-induced osteomalacia: In vitro inhibition by SFO of bone formation and 1.25-dihydroxy-vitamin D production in renal tubules. Bone. 1997;21:57\u201364. https:\/\/doi.org\/10.1016\/s8756-3282(97)00084-7.","journal-title":"Bone"},{"key":"1216_CR131","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3109\/00365521.2015.1031168","volume":"50","author":"W Reinisch","year":"2015","unstructured":"Reinisch W, Altorjay I, Zsigmond F, Primas C, Vogelsang H, Novacek G, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226\u201333. https:\/\/doi.org\/10.3109\/00365521.2015.1031168.","journal-title":"Scand J Gastroenterol"},{"key":"1216_CR132","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/jbmr.4558","volume":"37","author":"T Vilaca","year":"2022","unstructured":"Vilaca T, Velmurugan N, Smith C, Abrahamsen B, Eastell R. Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports. J Bone Miner Res. 2022;37:1188\u201399. https:\/\/doi.org\/10.1002\/jbmr.4558.","journal-title":"J Bone Miner Res"},{"key":"1216_CR133","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrendo.2011.218","volume":"8","author":"LD Quarles","year":"2012","unstructured":"Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol. 2012;8:276\u201386. https:\/\/doi.org\/10.1038\/nrendo.2011.218.","journal-title":"Nat Rev Endocrinol"},{"key":"1216_CR134","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1111\/bph.13268","volume":"172","author":"J Szebeni","year":"2015","unstructured":"Szebeni J, Fishbane S, Hedenus M, Locatelli F, Patni S, Rampton D, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol. 2015;172:5025\u201336. https:\/\/doi.org\/10.1111\/bph.13268.","journal-title":"Br J Pharmacol"},{"key":"1216_CR135","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjh.17202","volume":"193","author":"D Rund","year":"2021","unstructured":"Rund D. Intravenous iron: do we adequately understand the shirt- and long-term risks in clinical practice? Br J Haematol. 2021;193:466\u201380. https:\/\/doi.org\/10.1111\/bjh.17202.","journal-title":"Br J Haematol"},{"key":"1216_CR136","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000451069","volume":"45","author":"IC MacDougall","year":"2017","unstructured":"MacDougall IC, Vernon K. Complement Activation-Related Pseudo-Allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol. 2017;45:60\u20132. https:\/\/doi.org\/10.1159\/000451069.","journal-title":"Am J Nephrol"},{"key":"1216_CR137","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671\u20136. https:\/\/doi.org\/10.3324\/haematol.2014.111492.","journal-title":"Haematologica"},{"key":"1216_CR138","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","volume":"61","author":"J Szebeni","year":"2014","unstructured":"Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61:163\u201373. https:\/\/doi.org\/10.1016\/j.molimm.2014.06.038.","journal-title":"Mol Immunol"},{"key":"1216_CR139","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/vox.12773","volume":"114","author":"W Lim","year":"2019","unstructured":"Lim W, Afif W, Knowles S, Lim G, Lin Y, Mothersill C, et al. Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults. Vox Sang. 2019;114:363\u201373. https:\/\/doi.org\/10.1111\/vox.12773.","journal-title":"Vox Sang"},{"key":"1216_CR140","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jaip.2020.11.028","volume":"9","author":"S Stojanovic","year":"2021","unstructured":"Stojanovic S, Graudins LV, Kar Aung A, Grannell L, Hew M, Zubrinich C. Safety of intravenous iron following infusion reactions. J Allergy Clin Immunol Pract. 2021;9:1660\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.028.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1216_CR141","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/trf.15837","volume":"60","author":"M Achebe","year":"2020","unstructured":"Achebe M, DeLoughery TG. Clinical data for intravenous iron - debunking the hype around hypersensitivity. Transfusion. 2020;60:1154\u20139. https:\/\/doi.org\/10.1111\/trf.15837.","journal-title":"Transfusion"},{"key":"1216_CR142","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/17474086.2020.1738215","volume":"13","author":"D Durup","year":"2020","unstructured":"Durup D, Schaffalitzky de Muckadell P, Strom CC. Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigibaseTM and IQVIATM MIDAS\u00ae over a ten-year period from 2008 to 2017. Expert Revi Hematol. 2020;13:557\u201364. https:\/\/doi.org\/10.1080\/17474086.2020.1738215.","journal-title":"Expert Revi Hematol."},{"key":"1216_CR143","first-page":"301","volume":"100","author":"AM Ganzoni","year":"1970","unstructured":"Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100:301\u20133.","journal-title":"Schweiz Med Wochenschr"},{"key":"1216_CR144","first-page":"691","volume":"100","author":"AM Ganzoni","year":"1970","unstructured":"Ganzoni AM. Neue Aspekte des Eisenmangels. Schweiz Med Wochenschr. 1970;100:691\u20137.","journal-title":"Schweiz Med Wochenschr"},{"key":"1216_CR145","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/763576","author":"TA Koch","year":"2015","unstructured":"Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: Dosing considerations. Anemia. 2015. https:\/\/doi.org\/10.1155\/2015\/763576.","journal-title":"Anemia."},{"key":"1216_CR146","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","volume":"141","author":"R Evstatiev","year":"2011","unstructured":"Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846-53.e2. https:\/\/doi.org\/10.1053\/j.gastro.2011.06.005.","journal-title":"Gastroenterology"},{"key":"1216_CR147","doi-asserted-by":"publisher","first-page":"2020-11-3","DOI":"10.7573\/dic.2020-11-3","volume":"10","author":"X Kassianides","year":"2021","unstructured":"Kassianides X, Bhandari S, Edu MC. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs in Context. 2021;10:2020-11\u20133. https:\/\/doi.org\/10.7573\/dic.2020-11-3.","journal-title":"Drugs in Context."},{"key":"1216_CR148","doi-asserted-by":"crossref","unstructured":"Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth. 2014; http:\/\/www.biomedcentral.com\/1471-2393\/14\/115. Accessed 18\nAug 2022.","DOI":"10.1186\/1471-2393-14-115"},{"key":"1216_CR149","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00404-018-4782-9","volume":"298","author":"B Froessler","year":"2018","unstructured":"Froessler B, Gajic T, Dekker G, Hodyl NA. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. Arch Gynecol Obstet. 2018;298:75\u201382. https:\/\/doi.org\/10.1007\/s00404-018-4782-9.","journal-title":"Arch Gynecol Obstet"},{"key":"1216_CR150","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00404-020-05509-2","volume":"301","author":"J Wesstr\u00f6m","year":"2020","unstructured":"Wesstr\u00f6m J. Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy. Arch Gynecol Obstet. 2020;301:1127\u201331. https:\/\/doi.org\/10.1007\/s00404-020-05509-2.","journal-title":"Arch Gynecol Obstet"},{"key":"1216_CR151","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00431-017-2995-8","volume":"176","author":"M Li Nien Tan","year":"2017","unstructured":"Li Nien Tan M, Windscheif P, Thornton G, Gaynor E, Rodrigues A, Howarth L. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. Eur J Pediatr. 2017;176:1419\u201323. https:\/\/doi.org\/10.1007\/s00431-017-2995-8.","journal-title":"Eur J Pediatr"},{"key":"1216_CR152","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40272-022-00491-5","volume":"24","author":"P Panagopoulou","year":"2022","unstructured":"Panagopoulou P, Alexiadou S, Ntoumpara M, Papazoglou A, Makis A, Tragiannidis A, et al. Safety of ferric carboxymaltose in children: Report of a case series from Greece and review of the literature. Pediatr Drugs. 2022;24:137\u201346. https:\/\/doi.org\/10.1007\/s40272-022-00491-5.","journal-title":"Pediatr Drugs"},{"key":"1216_CR153","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/jpeds.2016.09.053","volume":"180","author":"JM Powers","year":"2017","unstructured":"Powers JM, Shamoun M, McCavit TL, Adix L, Buchanan GR. Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. J Pediatr. 2017;180:212\u20136. https:\/\/doi.org\/10.1016\/jpeds.2016.09.053.","journal-title":"J Pediatr"},{"key":"1216_CR154","doi-asserted-by":"publisher","first-page":"28","DOI":"10.21037\/tp.2019.01.01","volume":"8","author":"N Carman","year":"2019","unstructured":"Carman N, Muir R, Lewindon P. Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease. Transl Pediatr. 2019;8:28\u201334. https:\/\/doi.org\/10.21037\/tp.2019.01.01.","journal-title":"Transl Pediatr."},{"key":"1216_CR155","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","volume":"61","author":"JP Dwyer","year":"2013","unstructured":"Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis. 2013;61:759\u201366. https:\/\/doi.org\/10.1053\/j.ajkd.2012.11.041.","journal-title":"Am J Kidney Dis"},{"key":"1216_CR156","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1681\/ASN.2014020212","volume":"26","author":"JB Lewis","year":"2015","unstructured":"Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26:493\u2013503. https:\/\/doi.org\/10.1681\/ASN.2014020212.","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR157","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1681\/ASN.2014080842","volume":"26","author":"K Umanath","year":"2015","unstructured":"Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, et al. Ferric citrate reduces intravenous iron and erythopoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26:2578\u201387. https:\/\/doi.org\/10.1681\/ASN.2014080842.","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR158","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.ajkd.2015.09.031","volume":"67","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND, Kalantar-Zadeh K, Wish JB. New options for iron supplementation in maintenance hemodialysis patients. Am J Kidney Dis. 2016;67:367\u201375. https:\/\/doi.org\/10.1053\/j.ajkd.2015.09.031.","journal-title":"Am J Kidney Dis"},{"key":"1216_CR159","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2215\/CJN.15291219","volume":"15","author":"R Womack","year":"2020","unstructured":"Womack R, Berru F, Panwar B, Guti\u00e9rrez OM. Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD. Clin J Am Soc Nephrol. 2020;15:1251\u20138. https:\/\/doi.org\/10.2215\/CJN.15291219.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1216_CR160","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/kint.2021.10.036","volume":"101","author":"NR Hanudel","year":"2022","unstructured":"Hanudel NR, Czaya B, Wong S, Rappaport M, Namjoshi S, Chua K, et al. Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin. Kidney Int. 2022;101:711\u20139. https:\/\/doi.org\/10.1016\/kint.2021.10.036.","journal-title":"Kidney Int"},{"key":"1216_CR161","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1053\/j.ajkd.2012.03.024","volume":"60","author":"AJ Felsenfeld","year":"2012","unstructured":"Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis. 2012;60:655\u201361. https:\/\/doi.org\/10.1053\/j.ajkd.2012.03.024.","journal-title":"Am J Kidney Dis"},{"key":"1216_CR162","doi-asserted-by":"crossref","unstructured":"Prats M, Font R, Garcia C, Cabr\u00e9 C, Jariod M, Martinez Vea A. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: Post-hoc analysis of a prospective study. BMC Nephrol. 2013. http:\/\/www.biomedcentral.com\/1471-2369\/14\/167. Accessed 18 Aug 2022.","DOI":"10.1186\/1471-2369-14-167"},{"key":"1216_CR163","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.amjmed.2005.02.014","volume":"118","author":"A Gaasbeek","year":"2005","unstructured":"Gaasbeek A, Meinders AE. Hypophosphatemia: An update on its etiology and treatment. Am J Med. 2005;118:1094\u2013101. https:\/\/doi.org\/10.1016\/j.amjmed.2005.02.014.","journal-title":"Am J Med"},{"key":"1216_CR164","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1053\/j.ajkd.2010.11.024","volume":"57","author":"LV Riella","year":"2011","unstructured":"Riella LV, Rennke HG, Grafals M, Chandraker A. Hypophosphatemia in kidney transplant recipients: Report of acute phosphate nephropathy as a complication of therapy. Am J Kidney Dis. 2011;57:641\u20135. https:\/\/doi.org\/10.1053\/j.ajkd.2010.11.024.","journal-title":"Am J Kidney Dis"},{"key":"1216_CR165","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2215\/CJN.04981107","volume":"3","author":"US Alon","year":"2008","unstructured":"Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008;3:658\u201364. https:\/\/doi.org\/10.2215\/CJN.04981107.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1216_CR166","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2006-0021","volume":"91","author":"DM Antoniucci","year":"2006","unstructured":"Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91:3144\u20139. https:\/\/doi.org\/10.1210\/jc.2006-0021.","journal-title":"J Clin Endocrinol Metab"},{"key":"1216_CR167","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2004-1039","volume":"90","author":"SL Ferrari","year":"2005","unstructured":"Ferrari SL, Bonjour J, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90:1519\u201324. https:\/\/doi.org\/10.1210\/jc.2004-1039.","journal-title":"J Clin Endocrinol Metab"},{"key":"1216_CR168","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1210\/jc.2010-0589","volume":"95","author":"TO Carpenter","year":"2010","unstructured":"Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab. 2010;95:E352\u20137. https:\/\/doi.org\/10.1210\/jc.2010-0589.","journal-title":"J Clin Endocrinol Metab"},{"key":"1216_CR169","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Irmel EA, Boot AM, H\u00f6gler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378:1987\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1714641.","journal-title":"N Engl J Med"},{"key":"1216_CR170","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imei","year":"2019","unstructured":"Imei EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393:2416\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(19)30654-3.","journal-title":"Lancet"},{"key":"1216_CR171","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4233","author":"SMJ de Beur","year":"2020","unstructured":"de Beur SMJ, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, et al. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. 2020. https:\/\/doi.org\/10.1002\/jbmr.4233.","journal-title":"J Bone Miner Res"},{"key":"1216_CR172","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jbspin.2019.07.012","volume":"87","author":"AL Day","year":"2020","unstructured":"Day AL, Guti\u00e9rrez OM, Guthrie BL, Saag KG. Burosumab in tumor-induced osteomalacia: a case report. Joint Bone Spine. 2020;87:81\u20133. https:\/\/doi.org\/10.1016\/j.jbspin.2019.07.012.","journal-title":"Joint Bone Spine"},{"key":"1216_CR173","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1681\/ASN.V971264","volume":"9","author":"D Pri\u00e9","year":"1998","unstructured":"Pri\u00e9 D, Benqu\u00e9 Blanchet F, Essig M, Jourdain J, Friedlander G. Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J Am Soc Nephrol. 1998;9:1264\u20139. https:\/\/doi.org\/10.1681\/ASN.V971264.","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR174","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1359\/JBMR.070304","volume":"22","author":"JL Geller","year":"2007","unstructured":"Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams J, Collins MT. Clinical Vignette. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res. 2007;22:931\u20137. https:\/\/doi.org\/10.1359\/JBMR.070304.","journal-title":"J Bone Miner Res"},{"key":"1216_CR175","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1056\/NEJMc1010928","volume":"364","author":"ES Liu","year":"2011","unstructured":"Liu ES, Carpenter TO, Gundberg CM, Simpson CA, Insogna KL. Calcitonin administration in X-linked hypophosphatemia. N Engl J Med. 2011;364:1678\u201380. https:\/\/doi.org\/10.1056\/NEJMc1010928.","journal-title":"N Engl J Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01216-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01216-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01216-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T17:34:58Z","timestamp":1663781698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01216-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":175,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01216-w","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"19 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a physician-driven report and no funding was received.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This manuscript follows all ethical considerations as proposed by the World Health Organization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Johannes M.M. Boots received lecture fees and participated in advisory boards from Cablon Medical, The Netherlands; Pharmacosmos, Denmark; and Vifor Pharma, The Netherlands. Rogier A.M. Quax has no disclosures with regard to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The literature was partly taken from a previous publication. We conducted a search of Pubmed for additional literature on specific items to prove our message. In addition, the literature was recognized from references from trials and reviews. We tried to check opinions in reviews as much as possible by analyzing original reports. It was not intended to review all possible literature, since many reports reached the same conclusions and therefore not all reports are incorporated in this manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This report is driven by the recognition that physicians in clinical practice do not always make a proper risk\u2013benefit analysis when prescribing intravenous iron formulations. Many physicians from diverse specialties, such as internal medicine, gastroenterology, geriatrics, rheumatology, cardiology, gynecology, and even pediatrics, are unaware of the possible adverse effects and may harm their patients. It is intended to develop a practical guideline, based on a thorough evaluation of the literature, which can be implemented in daily practice or electronic prescription modules to prevent further harm in the future. Both authors contributed to the literature search, writing of the manuscript, and designing the figures, and read and approved the final version.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}